TrialCancer discovery2024

Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children's Oncology Group.

Elliot Stieglitz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.